Historical Valuation
IRadimed Corp (IRMD) is now in the Fair zone, suggesting that its current forward PE ratio of 53.06 is considered Fairly compared with the five-year average of 37.63. The fair price of IRadimed Corp (IRMD) is between 95.38 to 123.77 according to relative valuation methord.
Relative Value
Fair Zone
95.38-123.77
Current Price：100.36
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
IRadimed Corp (IRMD) has a current Price-to-Book (P/B) ratio of 12.35. Compared to its 3-year average P/B ratio of 8.13 , the current P/B ratio is approximately 51.91% higher. Relative to its 5-year average P/B ratio of 7.42, the current P/B ratio is about 66.36% higher. IRadimed Corp (IRMD) has a Forward Free Cash Flow (FCF) yield of approximately 1.21%. Compared to its 3-year average FCF yield of 1.80%, the current FCF yield is approximately -32.37% lower. Relative to its 5-year average FCF yield of 1.91% , the current FCF yield is about -36.37% lower.
P/B
Median3y
8.13
Median5y
7.42
FCF Yield
Median3y
1.80
Median5y
1.91
Competitors Valuation Multiple
AI Analysis for IRMD
The average P/S ratio for IRMD competitors is 7.68, providing a benchmark for relative valuation. IRadimed Corp Corp (IRMD.O) exhibits a P/S ratio of 13.81, which is 79.95% above the industry average. Given its robust revenue growth of 15.69%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for IRMD
1Y
3Y
5Y
Market capitalization of IRMD increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IRMD in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IRMD currently overvalued or undervalued?
IRadimed Corp (IRMD) is now in the Fair zone, suggesting that its current forward PE ratio of 53.06 is considered Fairly compared with the five-year average of 37.63. The fair price of IRadimed Corp (IRMD) is between 95.38 to 123.77 according to relative valuation methord.
What is IRadimed Corp (IRMD) fair value?
IRMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of IRadimed Corp (IRMD) is between 95.38 to 123.77 according to relative valuation methord.
How does IRMD's valuation metrics compare to the industry average?
The average P/S ratio for IRMD's competitors is 7.68, providing a benchmark for relative valuation. IRadimed Corp Corp (IRMD) exhibits a P/S ratio of 13.81, which is 79.95% above the industry average. Given its robust revenue growth of 15.69%, this premium appears unsustainable.
What is the current P/B ratio for IRadimed Corp (IRMD) as of Jan 10 2026?
As of Jan 10 2026, IRadimed Corp (IRMD) has a P/B ratio of 12.35. This indicates that the market values IRMD at 12.35 times its book value.
What is the current FCF Yield for IRadimed Corp (IRMD) as of Jan 10 2026?
As of Jan 10 2026, IRadimed Corp (IRMD) has a FCF Yield of 1.21%. This means that for every dollar of IRadimed Corp’s market capitalization, the company generates 1.21 cents in free cash flow.
What is the current Forward P/E ratio for IRadimed Corp (IRMD) as of Jan 10 2026?
As of Jan 10 2026, IRadimed Corp (IRMD) has a Forward P/E ratio of 53.06. This means the market is willing to pay $53.06 for every dollar of IRadimed Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for IRadimed Corp (IRMD) as of Jan 10 2026?
As of Jan 10 2026, IRadimed Corp (IRMD) has a Forward P/S ratio of 13.81. This means the market is valuing IRMD at $13.81 for every dollar of expected revenue over the next 12 months.